ahlam1399
04-22-2016, 10:22 PM
U.S. FDA staff sets voting questions for Sarepta?s muscle drug
April 22 (Reuters) – U.S. Food and Drug Administration staff
on Friday formulated voting questions on Sarepta Therapeutics
Inc’s muscle wasting drug, ahead of a highly
anticipated meeting of independent panel of experts on Monday to
review the drug.http://feeds.feedburner.com/~ff/reuters/companyNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/companyNews?a=1XwQjmGFBnk:rVK9It3eUmQ:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/companyNews?i=1XwQjmGFBnk:rVK9It3eUmQ:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/companyNews?a=1XwQjmGFBnk:rVK9It3eUmQ:V_sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/companyNews?i=1XwQjmGFBnk:rVK9It3eUmQ:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/companyNews?a=1XwQjmGFBnk:rVK9It3eUmQ:F7zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/companyNews/~4/1XwQjmGFBnk
April 22 (Reuters) – U.S. Food and Drug Administration staff
on Friday formulated voting questions on Sarepta Therapeutics
Inc’s muscle wasting drug, ahead of a highly
anticipated meeting of independent panel of experts on Monday to
review the drug.http://feeds.feedburner.com/~ff/reuters/companyNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/companyNews?a=1XwQjmGFBnk:rVK9It3eUmQ:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/companyNews?i=1XwQjmGFBnk:rVK9It3eUmQ:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/companyNews?a=1XwQjmGFBnk:rVK9It3eUmQ:V_sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/companyNews?i=1XwQjmGFBnk:rVK9It3eUmQ:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/companyNews?a=1XwQjmGFBnk:rVK9It3eUmQ:F7zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/companyNews/~4/1XwQjmGFBnk